Skip to main content

Table 2 Summary for results of PFGE fingerprint patterns and antibiotic susceptibility among clinical Acinetobacter baumannii isolates in the PFGE study

From: Tracing the emergence of multidrug-resistant Acinetobacter baumannii in a Taiwanese hospital by evaluating the presence of integron gene intI1

Number

P11

P2

P3

P4

P5

P6

P7

P8

P9

P10

P11

P12

Isolates year

2001

2001

2002

2002

2003

2003

2004

2004

2001

2002

2003

2004

PFGE type

A

B

C

B

A

A

B

D

A

A

E

A

Carrying-Int I1

+

+

+

+

+

+

+

+

-

-

-

-

AN

R2

R

R

R

R

S

R

R

R

S

R

S

SAM

R

R

R

R

R

R

R

R

R

R

R

R

CTZ

S

S

R

S

R

S

R

S

R

S

S

R

LVF

S

S

S

S

S

S

S

S

S

S

S

S

IMP

S

S

S

S

S

S

R

S

S

S

R

S

PIP-TAZ

S

R

S

R

S

R

S

R

S

R

S

S

CRO

S

S

R

S

R

S

R

S

R

S

S

R

  1. Notes:
  2. 1P number is the Lane number of PFGE study.
  3. 2S: Susceptible; R: Resistant; I: Belonged to resistant.
  4. 3The susceptibility tests were performed using the Vitek-2 GN card (Biomerieux, Marcy l'Etoile, France). The results were interpreted using the CLSI breakpoints (Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility testing).
  5. 4Abbreviation AN: amikacin; SAM: Ampicillin-sulbactam; CTZ: Ceftazidime; LVF: Levofloxacin; IMP: Imipenem-cilastatin; PIP-TAZ: Piperacillin-tazobactam; CRO: Ceftriaxone; colistin and tigecycline and polymyxin B were not provided by Vitek-2 System.